MedTrace Logo

Gastrointestinal STRING Test With Oral Immunotherapy

NCT04943744 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-09-19

No results posted yet for this study

Summary

This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.

Conditions

Interventions

DEVICE

Entero-tracker

Esophageal STRING test (Entero-tracker)

BIOLOGICAL

omalizumab

Used in the parent study

BIOLOGICAL

dupliumab

Used in the parent study

Sponsors & Collaborators

Principal Investigators

  • Sharon Chinthrajah, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-17
Primary Completion
2024-05-17
Completion
2024-05-17
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04943744 on ClinicalTrials.gov